Topics

Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ pic.twitter.com/GSMqDl5m39

05:54 EDT 13 Sep 2019 | Pharmafile

Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ 

Original Article: Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ pic.twitter.com/GSMqDl5m39

NEXT ARTICLE

More From BioPortfolio on "Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS http://bit.ly/2lOPQqJ pic.twitter.com/GSMqDl5m39"

Quick Search

Relevant Topics

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...